Pliant's Bexotegrast Shows Consistent Safety and Efficacy in Liver Disease Trial
Pliant Therapeutics' drug bexotegrast shows consistent safety across dose ranges in a Phase IIa trial for primary sclerosing cholangitis (PSC), although the highest dose did not demonstrate improved activity over lower doses based on new biomarker data. Analysts remain optimistic about the drug's overall development, as it inhibits two integrins to block the activation of TGF-beta, a central mediator of fibrosis in PSC patients.
